Alder Announces Presentations at 17th Congress of the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Alder Announces Presentations at 17th Congress of the International Headache Society on Data from ALD403 Clinical Trials

BOTHELL, Wash., May 6, 2015 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR ), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, today announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide (CGRP) antibody for the prevention of frequent episodic migraine, and Phase 1 data will be presented at the upcoming 17th Congress of the International Headache Society on May 14-15, 2015 in Valencia, Spain.

Oral presentation by Jeffrey T.L. Smith, M.D., FRCP, Senior Vice President, Translational Medicine at Alder: "Proof of Concept Clinical Trial of ALD403, an Anti-Calcitonin Gene-Related Peptide (CGRP) Antibody in the Prevention of Migraine – 6 Month Data"

Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target Presenter: Dr. Jeffrey Smith Date: Friday, May 15, 2015 Time: 10:10 a.m. CET (4:10 a.m. EDT) Location: Auditorium 1

Poster presentation: "A Single Dose Placebo-Controlled, Randomized, Ascending Dose Study of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody Administered IV or SC – Pharmacokinetic and Pharmacodynamic Results"

Poster Session: Migraine Preventive Therapy Abstract: 084 Date: Thursday, May 14, 2015 through Friday, May 15, 2015 Location: Multipurpose Room 1

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead clinical candidate, ALD403, inhibits a well-validated molecule shown to trigger migraine attacks, calcitonin gene-related peptide (CGRP), and is currently undergoing Phase 2b clinical testing for the treatment of chronic migraines. Alder plans to initiate additional advanced clinical studies for ALD403 in frequent episodic and chronic migraines in the second half of 2015. Alder's second program, ALD1613, which targets adrenocorticotropic hormone (ACTH) is undergoing Investigational New Drug (IND)-enabling preclinical studies with the initiation of clinical studies in Cushing's disease planned for 2016. Finally, clazakizumab, previously known as ALD518, is designed to block the pro-inflammatory cytokine IL-6 and has completed a Phase 2b clinical trial. For more information, please visit http://www.alderbio.com .

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the further development of clazakizumab, ALD403 and ALD1613, our expectations for the initiation of future clinical trials and studies, availability of clinical trial data, patient enrollment and the potential of ALD403, ALD1613 and clazakizumab to address the unmet medical needs of patients. All forward-looking statements included in this press release are based on our management's beliefs and assumptions and on information currently available to our management, and we assume no obligation to update any such forward-looking statements. Any or all of our forward-looking statements in this press release may turn out to be wrong and actual events or results may differ materially. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and other factors. In evaluating these statements, you should specifically consider various factors, including the risks outlined under the caption "Risk Factors" set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the Securities and Exchange Commission (SEC) on March 13, 2015, and is available on the SEC's website at www.sec.gov . Additional information will also be set forth in our other reports and filings we will make with the SEC from time to time. We caution investors that our business and financial performance are subject to substantial risks and uncertainties.

Media Contacts: David Schull or Lena Evans Russo Partners (212) 845-4271 (212) 845-4262 Investor Relations Contact: Sarah McCabe Stern Investor Relations, Inc. (212) 362-1200

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 173

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 50

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 74

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 21

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 43

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 229

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 44

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
NextPatient’s KLAS Marks Signal Specialty Workflow Fit

Updated Category News Views 35

A 93.3 score in healthcare software deserves a second look. Not a victory lap, not a drumroll—just a serious look at whether the product is solving an annoying, expensive operational problem for specialty practices. NextPatient’s recognition in the 2026 KLAS Emerging Solutions Top 20 Report lands in that category. The company placed in the top five for improving...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 102

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Crypto Volatility and the REX Osprey XRP ETF

Updated Category News Views 134

Cryptocurrency Market Overview and Recent Trends Up until October, the cryptocurrency market was experiencing significant growth, with a total capitalization reaching approximately $4.28 trillion. This surge was driven by abundant liquidity and a heightened risk appetite among investors. However, the capital markets can be unpredictable, leading to a swift and adverse...

Continue Reading
Intelligent Bio Inks Global Deal to Expand Drug Testing Solutions

Updated Category News Views 126

Intelligent Bio Solutions Launches Global Distribution Pact Intelligent Bio Solutions Inc. (NASDAQ: INBS) has recently announced an exciting global distribution partnership with SMARTOX. This collaboration aims to introduce their innovative SmarTest Patch, a cutting-edge product designed for drug detection, to international markets beyond the U.S. and Canada, marking a...

Continue Reading
Discover the Long-Term Growth of American Financial Group AFG Stock

Updated Category News Views 148

The Remarkable Journey of American Financial Group (AFG) American Financial Group (AFG) has significantly outperformed the market over the past twenty years, showing an annualized return of 9.37%, which surpasses the market by 1.29%. With a market capitalization standing at an impressive $10.39 billion, AFG is a noteworthy player in the financial sector. Investment...

Continue Reading
Current Sentiment Analysis: Canaan Inc's Short Interest Insights

Updated Category News Views 352

Canaan Inc's Current Short Interest Overview Canaan Inc (NYSE: CAN) is witnessing changes in its stock sentiment, particularly regarding its short interest. Recent reports indicate that the short interest, expressed as a percentage of the float, has dropped by 8.14%. Currently, 36.17 million shares are sold short, representing 8.58% of the total shares available for...

Continue Reading
CalExitNow Push for CA GOP Ban & Sovereignty Talks

Updated Category News Views 296

California's Political Pot Stirs In the wild world of politics, California stands as a fiery beacon yet again. This time, CalExitNow, a fiery group championing California's self-determination, is taking aim at the state’s Republican Party. Reminds me of a stock under pressure—hesitate at your peril as the winds of change sweep through. Disqualification Petition: A...

Continue Reading